Pertuzumab Biosimilar QL1209 Demonstrated Equivalent Efficacy, Safety to Reference Pertuzumab Among Patients With HER2-Positive Breast Cancer
Recommended
Pertuzumab Biosimilar QL1209 Demonstrated Equivalent Efficacy, Safety to Reference Pertuzumab Among Patients With HER2-Positive Breast Cancer
According to a phase 3 equivalence study, the pertuzumab biosimilar QL1209 was comparable to reference pertuzumab in efficacy, safety, and immunogenicity among patients with early or locally advanced HER2-positive breast cancer.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->